Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlaxoSmithKline (GSK) and Human Genome Sciences (HGS) have received the European Commission (EC) approval to market Benlysta (belimumab) 10mg/kg.
Subscribe to our email newsletter
The approval for Benlysta was granted as an additional therapy for the adult patients suffering from active autoantibody-positive systemic lupus erythematosus (SLE) with high degree of disease activity.
Benlysta is under development by GSK and HGS as per a co-development deal signed between the companies in 2006.
GSK European Medical Affairs senior VP Tony Hoos said the European approval of Benlysta represents a significant milestone, and they are very pleased to be able to provide physicians an additional therapeutic option for treating appropriate patients with this chronic disease.